Exploring CD33 CAR-T Cell Therapy for Acute Myeloid Leukemia

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial is a single-arm, open-label, dose-escalation study aimed at evaluating the safety and efficacy of CD33 CAR-T cells in patients with relapsed or refractory acute myeloid leukemia (AML). The trial plans to enroll between 15 to 27 participants who meet specific eligibility criteria, including a confirmed diagnosis of CD33 positive AML. Participants will receive CD33 CAR-T cell therapy, and the study will monitor their response and any adverse effects throughout the treatment process.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* 1\. Male or female, age ≥ 18 years old;
* 2\. CAR-T cells can be prepared normally, or who have failed to prepare autologous CAR-T cells (including the number of autologous lymphocytes \<1×10\^9 or the expansion during the preparation process is insufficient or cannot reinfusion);
* 3\. Patients diagnosed with CD33 positive acute myeloid leukemia (AML) through histological or immunological examination，and CD33 positive expression rate \>80%;
* 4\. Complies with the 2016 WHO classification for AML diagnosis and meets the diagnostic criteria for recurrence and refractory acute myeloid leukemia in the "Chinese Guidelines for the Diagnosis and Treatment of relapsed and refractory acute myeloid leukemia (2017 edition)", and currently there are no clinically relevant treatments or suitable clinical trials for registration:
* a) Diagnostic criteria for recurrent AML: After complete remission (CR), leukemia cells reappear in peripheral blood or primitive cells in bone marrow\>0.050 (excluding other reasons such as bone marrow regeneration after consolidation chemotherapy) or leukemia cell infiltration appears outside the bone marrow;
* b) Diagnostic criteria for refractory AML: initial treatment cases that have failed to respond to two courses of standard protocol treatment; Patients who relapse within 12 months after consolidation and intensive treatment after CR; Patients who relapse after 12 months but fail conventional chemotherapy; Patients with 2 or more relapses; Persistent extramedullary leukemia;
* 5\. The number of primitive cells (promyelocytes and/or promyelocytes) in the bone marrow \> 5% (morphology) and/or \> 1% (flow cytometry detection);
* 6\. Total bilirubin ≤ 51 μmol / L, ALT and AST ≤ 3 times of the upper limit of normal value, serum creatinine ≤ 176.8 μmol / L；
* 7\. Echocardiography shows left ventricular ejection fraction (LVEF) ≥ 50%;
* 8\. There is no active pulmonary infection, and the oxygen saturation during air inhalation is more than 92%;
* 9\. The estimated survival time is more than 3 months;
* 10\. ECOG score was 0-2;
* 11\. Pregnant/lactating women, or male or female patients who have fertility and are willing to take effective contraceptive measures at least 6 months after the last cell infusion during the study period;
* 12\. Those who voluntarily participated in this trial and provided informed consent;

Exclusion Criteria:

* 1\. Patients with the history of epilepsy or other CNS disease;
* 2\. Patients with prolonged QT interval time or severe heart disease;
* 3\. Active infection with no cure;
* 4\. Active infection of hepatitis B virus or C virus ;
* 5\. Before using any gene therapy products;
* 6\. The proiferation rate is less than 5 times response to CD3/CD28 co-stimulation signal;
* 7\. Suffering from other uncontrolled diseases that the researchers consider unsuitable for joining;
* 8\. Infected with AIDS virus;
* 9\. Any situation that researchers believe may increase the risk to the subjects or interfere with the trial results.

Where it's running

• The first affiliated hospital of medical college of zhejiang university
  Hangzhou, Zhejiang, China Recruiting

Study contacts

• Principal investigator: He Huang, MD — First Affiliated Hospital of Zhejiang University
• Study coordinator: He Huang, MD
• Email: hehuangyu@126.com
• Phone: 057187233772

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• In Vivo CD19/CD20 CAR T-Cell Therapy for Relapsed or Refractory B-Cell Lymphoma

  This early-phase trial tests a one-time in vivo CAR T-cell therapy (SL1617) for people with relapsed or refractory B-cell lymphoma to see if it is safe and tolerable.

  Recruiting Phase 1 Chinese PLA General Hospital · Beijing · NCT07775508

• Donor-derived CD117 CAR-T cells for relapsed or refractory acute myeloid leukemia

  This trial will try donor-derived CD117 CAR-T cells to treat patients with CD117-positive relapsed or refractory acute myeloid leukemia.

  Recruiting Early Phase 1 Zhejiang University · Hangzhou, Zhejiang · NCT07144020

• CD5 CAR T-cell therapy for relapsed or refractory T-cell lymphoma

  This trial tries CD5 CAR T-cell therapy, using either the patient's own cells or donor cells, and may bridge to stem-cell transplant for people 14–70 with relapsed or refractory T-cell lymphoma.

  Recruiting at 3 sites Phase 1/2 Beijing GoBroad Hospital · Beijing and 2 other locations · NCT07022964

• Glofitamab plus obinutuzumab for mantle cell lymphoma after CAR‑T

  This trial tests whether the antibody drug glofitamab given with obinutuzumab can shrink or control mantle cell lymphoma that returned or didn't respond after CD19 CAR‑T therapy in adults.

  Recruiting at 11 sites Phase 2 National Cancer Institute (NCI) · Duarte, California and 10 other locations · NCT07003295

• CD7 CAR T-Cell Therapy for T-Cell Lymphomas

  This study is testing a new CAR T-cell therapy for people with T-cell lymphomas that haven't responded to regular treatments to see if it is safe and effective.

  Recruiting at 4 sites Phase 1/2 Beijing GoBroad Hospital · Beijing, Beijing Municipality and 3 other locations · NCT06925464

• CLL1 and CD38 dual-target CAR-T treatment for relapsed or refractory acute myeloid leukemia

  This trial will test an infusion of CLL1 and CD38 dual-target CAR-T cells in adults with relapsed or refractory acute myeloid leukemia to see if it is safe and shows early signs of benefit.

  Recruiting Phase 1 Institute of Hematology & Blood Diseases Hospital, China · Tianjin · NCT06880354

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.